NCT06198868Recruiting
MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC
Minimal Residual Disease (MRD) Guided Prognosis Prediction and Adjuvant Treatment Based on Expression and Mutational Signatures of Circulating Tumor Cell (CTC) and Circulating Tumor DNA (ctDNA) in Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 12 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a prospective cohort study, which aims to evaluate the effectiveness and superiority of a novel minimal residual disease-guided prognosis monitoring and adjuvant treatment in stage IIA-IIIC non-small cell lung cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 28 Dec 2023
- Start date
- 1 Feb 2024
- Primary completion date
- 1 Feb 2026
- Lead sponsor
- Jiangsu Cancer Institute & Hospital
- Diseases
- Lung cancer
- NCT number
- NCT06198868
What you commit to
- Study type: Observational
- Planned participants: 60
- From 1 Feb 2024 to the primary completion date, 1 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received surgical treatment for lung tumors.
- Received neoadjuvant chemotherapy or radiotherapy.
- Received cellular therapy within the last 1 year.
- Participated in other clinical trials (including research vaccines, drugs, medical devices, etc.) within one month.
Other illness
- Treated but uncontrolled diabetes, mellitus, asthma, autoimmune diseases and other chronic diseases.
Who the study is looking for
- Written informed consent must be signed before implementing any enrollment-related procedures;
- Age ≥18 years old;
- Patients with histologically or cytologically confirmed stage IIA-IIIC NSCLC (International Association for the Study of Lung Cancer and American Joint Committee on Classification of Cancer, 8th Edition TNM staging)；
- There is no special restriction on the source of genetic test report.
- According to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1), there is at least one radiographically measurable lesion.
- Have not received any previous systemic antitumor therapy for advanced diseases.
- No serious abnormalities of hematopoietic function, heart, lung, liver, kidney function and immune system.
- ECOG score: 0-1;
- Expected survival time \> 3 months.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiangsu Cancer Institute & Hospital Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.